A detailed history of Marshall Wace, LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 33,868 shares of NVCT stock, worth $247,236. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,868
Previous 50,068 32.36%
Holding current value
$247,236
Previous $410,000 47.8%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.98 - $8.25 $96,876 - $133,650
-16,200 Reduced 32.36%
33,868 $214,000
Q1 2024

May 15, 2024

BUY
$6.69 - $11.0 $168,955 - $277,805
25,255 Added 101.78%
50,068 $410,000
Q4 2023

Feb 14, 2024

SELL
$7.85 - $11.78 $88,485 - $132,784
-11,272 Reduced 31.24%
24,813 $206,000
Q3 2023

Nov 14, 2023

SELL
$12.89 - $16.29 $73,344 - $92,690
-5,690 Reduced 13.62%
36,085 $465,000
Q2 2023

Aug 14, 2023

BUY
$12.62 - $18.4 $527,200 - $768,659
41,775 New
41,775 $667,000

Others Institutions Holding NVCT

About Nuvectis Pharma, Inc.


  • Ticker NVCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,642,500
  • Market Cap $107M
  • Description
  • Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...
More about NVCT
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.